据智通财经，11月25日，记者获悉，随着流感季提前到来，阿里健康平台上的相关药品需求呈现明显上 升趋势。阿里健康平台数据显示，近两周（11.10-11.23）流感应季药品的关注度和购买量均有明显提 升。总体而言，流感抗病毒药物购买人数呈现超500%的环比增长。其中玛巴洛沙韦表现尤为突出，购 买人数环比增长超600%，增速领先；抗病毒口服液购买人数环比50%。反映出消费者对流感的防治意 识进一步增强。专家指出，今年流行的甲型H3N2毒株与往年不同，人群普遍免疫力较低，更易引发传 播，值得公众警惕。 （文章来源：第一财经） ...

Core Viewpoint - Alibaba Health and Taobao Flash Purchase have launched a new service called "Home Flash Testing," which allows users to conduct professional-level respiratory virus and bacteria testing from home, providing timely reports to ease the pressure on healthcare systems during flu season [1][2]. Group 1 - The "Home Flash Testing" service is currently in trial operation in four cities: Beijing, Shanghai, Guangzhou, and Hangzhou [1]. - Users can book the service through the Taobao App, where trained couriers will deliver sampling kits and assist in sample collection, with results available online within an average of three hours [1]. - The "Respiratory Virus and Bacteria 12-in-1 Test" covers 12 common respiratory pathogens, including various strains of influenza and COVID-19, addressing diverse testing needs during peak seasons [1]. Group 2 - The launch of "Home Flash Testing" represents a deep collaboration between Taobao Flash Purchase and Alibaba Health in the localized healthcare service sector [2]. - Future plans include integrating more professional medical services into instant retail scenarios, aiming to create a seamless "testing—medical—pharmacy" service loop for more convenient and efficient local health services [2].

Core Insights - Alibaba Health and Bayer are deepening their collaboration in the field of women's health through digital innovation [1][2] - The partnership aims to explore the potential of women's health management, AI-assisted consultations, and patient education [1] - Both companies recognize the importance of digital platforms in enhancing accessibility and experience for female patients [1][2] Group 1: Collaboration Details - Bayer's Vice President and General Manager of Women's Health in China, Yuan Junjie, emphasized the growing societal attention on women's health in China [2] - The collaboration is seen as a significant step in creating a comprehensive health service system that integrates medicine, pharmaceuticals, insurance, and wellness [2] - The exchange marks a new phase in the partnership, focusing on technology-enabled healthcare solutions [2] Group 2: Technological Integration - Alibaba Health showcased its achievements in women's health and its overall layout in the internet medical ecosystem, including online consultations and chronic disease management [1] - Bayer's team acknowledged Alibaba Health's technological capabilities in smart triage, symptom self-screening, and personalized health consultations [1] - Both parties expressed a willingness to jointly explore AI-assisted health management scenarios for specific gynecological diseases [1]

格隆汇11月14日丨阿里健康(00241.HK)公布，董事会将于2025年11月26日(星期三)举行董事会会议，旨 在考虑及通过(其中包括)公司及其附属公司截至2025年9月30日止六个月的未经审核中期业绩，以及考 虑建议派付中期股息(如有)。 ...

（股份代號：00241） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） 沈滌凡 香港，2025年11月14日 於本公告日期，董事會成員包括：執行董事沈滌凡先生及屠燕武先生；非執行董事 朱順炎先生、黃佼佼女士及徐海鵬先生；及獨立非執行董事黃一緋女士、邵蓉博士 及吳亦泓女士。 董事會召開日期 阿里健康信息技術有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此公佈，董事 會將於2025年11月26日（星期三）舉行董事會會議，旨在考慮及通過（其中包括）本公 司及其附屬公司截至2025年9月30日止六個月之未經審核中期業績，以及考慮建議 派付中期股息（如有）。 承董事會命 阿里健康信息技術有限公司 首席執行官兼執行董事 ...

Group 1 - Alibaba Health has formed partnerships with multinational pharmaceutical companies including Eurofarma, Pfizer, and Novo Nordisk [1] - The collaborations focus on areas such as cardiovascular disease management, migraine treatment, and diabetes and obesity [1] - These partnerships aim to further expand the boundaries of digital health services [1]

Core Insights - Alibaba Health and Ocalon have initiated a strategic partnership focused on cardiovascular health management, leveraging their respective strengths in digital health and chronic disease management [1][2] - The collaboration aims to enhance patient care through data-driven solutions and comprehensive health management strategies [1][2] Group 1: Company Overview - Alibaba Health is a leading internet pharmaceutical health service platform in China, known for its strong digital capabilities and extensive ecosystem [2] - The company has established partnerships with thousands of pharmaceutical enterprises globally, providing full-chain support from drug launch to patient services [1][2] Group 2: Strategic Partnership Details - The partnership will utilize Alibaba Health's digital ecosystem and platform operations alongside Ocalon's expertise in cardiovascular treatment to support long-term patient management outside of hospitals [1][2] - Both companies aim to enhance the online medical service landscape, focusing on optimizing health management solutions for cardiovascular disease patients [2] Group 3: Future Directions - The collaboration signifies a new phase in cardiovascular disease management, with both companies committed to exploring more efficient and precise long-term management pathways through technology and data [2] - The partnership is expected to contribute to the broader goal of promoting a healthier China by improving public awareness and understanding of cardiovascular diseases [2]

Core Insights - Novo Nordisk has announced a comprehensive upgrade and expansion of its "Health Ecosystem Alliance," with Alibaba Health as a core partner, focusing on chronic disease management, particularly diabetes and obesity [2] Group 1: Strategic Collaboration - Alibaba Health and Novo Nordisk have maintained close cooperation in chronic disease patient services, achieving significant results in patient education, medication accessibility, and disease awareness [2] - In June of this year, Alibaba Health and Novo Nordisk formalized a new round of strategic cooperation, creating a one-stop weight management knowledge and service area [2] Group 2: Digital Innovation - Novo Nordisk's Senior Vice President and President of Greater China, Zhou Xiaping, emphasized that digital innovation injects new momentum into chronic disease management and supports the enhancement of public health literacy [2] - The collaboration aims to develop a smart medical solution covering the entire life cycle, enhancing awareness of obesity and diabetes, and promoting early screening, diagnosis, and treatment [2] Group 3: User-Centric Approach - Alibaba Health's head of Internet hospital and consumer healthcare, Zhang Wen, highlighted the company's long-term focus on chronic disease management, leveraging a vast user base and digital operational capabilities to provide personalized solutions [2] - The strategic partnership exemplifies the "Internet + Health Care" model in digital chronic disease management, aiming to offer more accessible, convenient, and empathetic health management services for patients with diabetes and obesity [2]

Core Insights - Alibaba Health and Pfizer have formed a strategic partnership to enhance migraine treatment accessibility and digital disease management in China [1][2] - The collaboration will focus on the launch of Pfizer's new migraine-specific treatment, Rimegepant orally disintegrating tablets, in China, expected to be approved in 2024 [1] - The partnership aims to create a comprehensive digital health model integrating medical services, pharmaceuticals, and patient education [1][2] Group 1 - The partnership will leverage Alibaba Health's extensive distribution network and instant retail capabilities to ensure rapid access to Rimegepant during acute migraine episodes [2] - Alibaba Health has reached over 300 million users, significantly improving the accessibility and coverage of innovative medications [2] - The collaboration will also focus on educating the public about migraines, addressing misconceptions, and promoting standardized treatment [2] Group 2 - Future expansions of the partnership will target other therapeutic areas such as inflammation, immunology, and rare diseases [2] - Alibaba Health will utilize deep insights into user behavior to create personalized health management plans for specific patient groups [2] - The partnership will provide 24/7 medication guidance through a professional pharmacist team to ensure safe and appropriate medication use [2]

Core Insights - Alibaba Health and Pfizer have formed a strategic partnership to enhance migraine treatment accessibility and digital disease management in China [1][3] - The collaboration will focus on the launch of Pfizer's new migraine-specific treatment, Rimegepant, in the Chinese market [1][3] Group 1: Strategic Collaboration - The partnership aims to explore a new digital health model integrating "medicine-pharmaceutical-patient" [1] - The initial focus will be on migraine treatment, with plans to expand into other therapeutic areas such as inflammation, immunity, and rare diseases [3] Group 2: Operational Synergies - Alibaba Health will leverage its nationwide distribution network and instant retail capabilities to ensure rapid access to Rimegepant during acute migraine episodes [3] - The collaboration will include personalized health management plans based on deep insights into user behavior [3] Group 3: Patient Support and Education - Joint initiatives will involve disease education and 24/7 medication guidance provided by a professional pharmacist team [3] - The goal is to create a comprehensive health management cycle from disease awareness to standardized treatment [3]